Isoniazid/pyridoxine/sulfamethoxazole/trimethoprim (INH/B6/CTX) is a fixed dose combination medication for the prevention of opportunistic infections in HIV/AIDS. It combines isoniazid, pyridoxine, sulfamethoxazole, and trimethoprim. Specifically it is used to prevent tuberculosis, toxoplasmosis, pneumonia, malaria, and isosporiasis. It is taken by mouth.
Side effects may include trouble concentrating, numbness, vomiting, and rash. Serious side effects may include liver problems. Caution may be required in people with G6PD deficiency. While it has not been well studied, use in pregnancy appears to be okay.
It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. A year of medication is estimated to cost about 15 USD in the developing world as of 2016. While benefits include being able to take less pills, it is unclear if this version changes peoples adherence to treatment. Other studies, however, have found fixed dose combinations to be useful for this purpose.
- "WHO Model List of Essential Medicines (20th List)" (PDF). World Health Organization. March 2017. Retrieved 29 June 2017.
- "WHO Model List of Essential Medicines Application" (PDF). March 2011. Retrieved 29 June 2017.
- "WHO Model List of Essential Medicines Application" (PDF). Retrieved 13 December 2017.
- "WHO application for the inclusion of INH/CTX/B6 FDC in the WHO Essential Medicines List" (PDF). Retrieved 13 December 2017.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|